HAVCR2 and neoplasm: We recently reported that in patients with advanced BCa, cabozantinib treatment modulated immune checkpoint regulators PD-1 and TIM-3, increased anti-tumor monocytes, and decreased pro-tumorigenic monocytes and myeloid-derived suppressor cell (MDSC) populations; a greater-than-median decrease in the granulocytic MDSC population was significantly associated with a favorable outcome [23].